Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
•
Diabetes
•
Endocrinology
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
Related Questions
Would you give any adjuvant therapy (chemo, immunotherapy and/or radiation) to a patient with pure small cell cancer of the urinary bladder who received neoadjuvant cisplatin and etoposide but had pN+ and residual invasive disease on cystectomy?
What is the optimal approach to systemic therapy for metastatic squamous cell carcinoma of the bladder considering the approval of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma?
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
What is your approach to muscle-invasive bladder cancer in a patient who is ineligible for surgery and radiotherapy?
Would you consider a treatment break for a patient with metastatic urothelial carcinoma who achieved a near-complete response to Enfortumab?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
Do you offer neoadjuvant chemotherapy to nested variant urothelial carcinoma (NVUC) of the bladder?
Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?
What are your top takeaways in GU Cancers from ESMO 2024?
Given results of BCON trial, do you add carbogen and nicotinamide for patients receiving definitive radiotherapy for bladder cancer, particularly for non-cisplatin eligible candidates?
